https://scholars.lib.ntu.edu.tw/handle/123456789/496120
標題: | Thyroid Cancer Risk Is Not Increased in Diabetic Patients | 作者: | CHIN-HSIAO TSENG | 公開日期: | 2012 | 卷: | 7 | 期: | 12 | 起(迄)頁: | e53096 | 來源出版物: | PLoS ONE | 摘要: | Objective: This study evaluated thyroid cancer risk with regards to diabetes status and diabetes duration, and with the use of anti-diabetic drugs including sulfonylurea, metformin, insulin, acarbose, pioglitazone and rosiglitazone, by using a population-based reimbursement database in Taiwan. Methods: A random sample of 1,000,000 subjects covered by the National Health Insurance was recruited. After excluding patients with type 1 diabetes, 999730 subjects (495673 men and 504057 women) were recruited into the analyses. Logistic regression estimated the odds ratios (OR) and their 95% confidence intervals (CI) for independent variables including age, sex, diabetes status/duration, anti-diabetic drugs, other medications, comorbidities, living regions, occupation and examinations that might potentially lead to the diagnosis of thyroid cancer in various models. Results: The diabetic patients had a significantly higher probability of receiving potential detection examinations (6.38% vs. 5.83%, P<0.0001). After multivariable-adjustment, the OR (95% CI) for diabetes status was 0.816 (0.652-1.021); and for diabetes duration <1 year, 1-3 years, 3-5 years and ?5 years vs. non-diabetes was 0.071 (0.010-0.507), 0.450 (0.250-0.813), 0.374 (0.203-0.689) and 1.159 (0.914-1.470), respectively. Among the anti-diabetic agents, only sulfonylurea was significantly associated with thyroid cancer, OR (95% CI): 1.882 (1.202-2.947). The OR (95% CI) for insulin, metformin, acarbose, pioglitazone and rosiglitazone was 1.701 (0.860-3.364), 0.696 (0.419-1.155), 0.581 (0.202-1.674), 0.522 (0.069-3.926) and 0.669 (0.230-1.948), respectively. Furthermore, patients with benign thyroid disease or other cancer, living in Kao-Ping/Eastern regions, or receiving potential detection examinations might have a significantly higher risk; and male sex, hypertension, dyslipidemia, chronic obstructive pulmonary disease, vascular complications or use of statin, aspirin or non-steroidal anti-inflammatory drugs might be associated with a significantly lower risk. Conclusions: There is a lack of an overall association between diabetes and thyroid cancer, but patients with diabetes duration <5 years have a significantly lower risk. Sulfonylurea may increase the risk of thyroid cancer. ? 2012 Chin-Hsiao Tseng. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871658952&doi=10.1371%2fjournal.pone.0053096&partnerID=40&md5=c0237f8a9a176a7e000952c756520f1b https://scholars.lib.ntu.edu.tw/handle/123456789/496120 |
ISSN: | 1932-6203 | DOI: | 10.1371/journal.pone.0053096 | SDG/關鍵字: | acarbose; acetylsalicylic acid; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin; metformin; nonsteroid antiinflammatory agent; pioglitazone; rosiglitazone; sulfonylurea; article; cancer risk; cerebrovascular accident; chronic lung disease; comorbidity; diabetes mellitus; diabetic patient; disease association; disease course; disease duration; drug use; dyslipidemia; eye disease; female; high risk patient; human; hypertension; ischemic heart disease; kidney disease; major clinical study; male; peripheral occlusive artery disease; risk assessment; sex difference; thyroid cancer; thyroid disease; vascular disease; Adult; Aged; Aged, 80 and over; Comorbidity; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Physical Examination; Risk; Sex Factors; Taiwan; Thyroid Neoplasms |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。